Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies

Although KRAS-activating mutations represent the most common oncogenic driver in non-small cell lung cancer (NSCLC), various attempts to inhibit KRAS failed in the past decade. KRAS mutations are associated with a poor prognosis and a poor response to standard therapeutic regimen. The recent develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Désage, Anne-Laure, Léonce, Camille, Swalduz, Aurélie, Ortiz-Cuaran, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889932/
https://www.ncbi.nlm.nih.gov/pubmed/35251972
http://dx.doi.org/10.3389/fonc.2022.796832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889932/
https://www.ncbi.nlm.nih.gov/pubmed/35251972
http://dx.doi.org/10.3389/fonc.2022.796832

Ejemplares similares